OKYO Stock Forecast & Price Target

OKYO Pharma Ltd has made significant progress in the clinical development of its therapeutic candidate urcosimod, particularly in the treatment of chronic pain. The data indicates that 67% of patients receiving the 0.05% concentration of urcosimod experienced more than a 50% reduction in pain, compared to just 33% in the placebo group, showcasing the efficacy of the treatment. Additionally, noticeable pain relief was observed as early as Week 4, suggesting a strong potential for positive patient outcomes and market demand in the biopharmaceutical sector.

OKYO Pharma Ltd reported a significant net loss of $4.7 million, equating to $0.12 per share, for the fiscal year ending March 31, 2025, indicating ongoing financial challenges. The company's 0.05% urcosimod group displayed a worse baseline pain condition compared to the placebo group, raising concerns about the therapeutic's efficacy. Additionally, multiple risks, including the potential failure of urcosimod in clinical trials and its ability to secure regulatory approval, further support a negative outlook on the stock.